Replies to post #1840 on Lisata Therapeutics Inc (LSTA)

[James salmon]

No idea. I rode Advaxis threw several offerings, and RS when it was between $2.50 and $5, it's now $22+.

Biotechs are a waiting game. If a company has great science then it will prevail. To me Neostem has the science, it now is all about execution. Also to be honest after this round of financing they should be good until end of Phase 3, and fully diluted share count is not bad.